KZIA
Kazia Therapeutics Ltd
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Kazia Therapeutics Ltd
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
—
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
No changes.
No changes.
No thesis.
No peers for Kazia Therapeutics Ltd yet.
No peers for Kazia Therapeutics Ltd yet.
Annual filing, covered
20-F parsed · Nov 7 '25
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
20-F parsed · Nov 7 '25
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
—
Expected move
No implied move.
Kazia Therapeutics Ltd
8.54
Largest filed tie
—
News
News—
—
| Manager | Value | % base | |
|---|---|---|---|
| Boxer | $7.9M | 13.88% | new |
| Putnam FL | $5.8M | 10.28% | +191.26% |
| Bleichroeder | $5.6M | 9.91% | 0.00% |
| Ikarian Capital | $5.6M | 9.82% | new |
| Dauntless Investment | $5.0M | 8.78% | +343.69% |
| Manager | Value | % base | |
|---|---|---|---|
| Boxer | $7.9M | 13.88% | new |
| Putnam FL | $5.8M | 10.28% | +191.26% |
| Bleichroeder | $5.6M | 9.91% | 0.00% |
| Ikarian Capital | $5.6M | 9.82% | new |
| Dauntless Investment | $5.0M | 8.78% | +343.69% |